Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Analysts are expecting strong results driven by the continued success of Lilly's blockbuster medications, particularly the diabetes franchise. However, there are also concerns about potential pre… Read More